1 / 10

Seroprevalance of Hepatitis C in Turkey (%) (Anti-HCV positivity in donors)

Adana (n:8310) Antalya (n:16.410) Bursa (n:16.512) Erzurum (n:24.870) İstanbul (n:108.000) Trabzon (n:22.300) Ankara (n:14.372). Seroprevalance of Hepatitis C in Turkey (%) (Anti-HCV positivity in donors).

Download Presentation

Seroprevalance of Hepatitis C in Turkey (%) (Anti-HCV positivity in donors)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Adana (n:8310) Antalya (n:16.410) Bursa (n:16.512) Erzurum (n:24.870) İstanbul (n:108.000) Trabzon (n:22.300) Ankara (n:14.372) Seroprevalance of Hepatitis C in Turkey (%)(Anti-HCV positivity in donors)

  2. Annual Anti-HCV Positivity rate at Istanbul–Çapa Red Crescent Blood Bank Year Total nbr of blood units Seropositive (%) 1997 73,959 0.4 1998 62,786 0.6 1999 55,953 0.4 2000 51,460 0.4 2001 51,037 0.4 Overall, 0.3% of 457,240 units from Red Crescent blood banks positive for Anti-HCV.

  3. Characteristics of seropositive cases No difference by sex or educational status  Age 18-28 : 0,2% 29-30 : 0,3% 40-50 : 0,4% 51-55 : 0,6%  First-time donors : 0,2 %  Soldiers : 2,4 %  Professional donors : 20 %

  4. Anti-HCV Seropositivity in different groups (%)-I Haemodialysis patients (overall 41% positive in 2073 cases) n% Ankara 418 34,7 Bursa 110 82,8 Adana 180 14,4 İstanbul 150 36,0 İzmir 81 49,3 Diyarbakır 55 32,7 Kayseri 76 32,9 Sivas 65 56,9 Trabzon 80 20

  5. Anti-HCV Seropositivity in different groups (%)-II %  Health personnel (n>3290) 0,9  Sex workers (n> 800) 4,8  Prisoners 3,1  Diabetic patients 11,6  Hepatocellular carsinoma 12,5-29  Renal transplantation 12,5-52,7  Cryptogenic cirrhosis 26,9  Talassemia patients 16,6-57,1  IV drug users 54,8

  6. Diagnostic methods of HCV infections in Turkey • Screening : Anti-HCV ELİSA (3rd,4th generation kits) • Monitorization of treatment (HCV –RNA viral load) ; Cobas –Amplicor monitoring / b.DNA-Bayer • Treatment :INF + Ribavirin • Genotype distribution :> 70 %: 1b

  7. Liver cirrhosis in Turkey (%) Years Aetiology 1983-89 1990-93 1994-97 (n=616) (n=436) (n=393) Viral 42,9 56,7 59,5 Cryptogenic 41,2 22,7 16,8 Alcoholic 8,9 12,6 10,9 Misc. 7 8 12,8

  8. Viral Agents in Liver Cirrhosis (%) 1990-93 1994-1997 HBV 56,5 42,6 HCV 25,2 34,5 HDV 14,6 15,7 HBV + HCV 3,7 1,2 Alcoholic + Viral __ 6

  9. Etiologic Distribution of the Chronic Hepatitis (%) 1991-1994 1994-1997 ( n: 296) (n: 527) Type B 56 46,5 Type C 23 35 Cryptogenic C.H. 9 8,9 Type B+D 6,8 4,5 Type B+C 3 3 Autoimmune 1,5 1,5 Drug induced 0,7 0,2 B+C+D _ 0,4

  10. Summary Hepatitis B still keeps the first place in the etiology of chronic hepatitis in Turkey. The ratio of hepatitis B and D decreases among the other causes of chronic hepatitis. The ratio of hepatitis C increases as a cause of chronic hepatitis. The ratio of crytogenic and autoimmune hepatitis remain the same.

More Related